MedTrace Logo

Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals

NCT03125629 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2021-04-09

Study results available
· View outcomes & findings →

Summary

This clinical trial studies how well positron emission tomography (PET)/computed tomography (CT) works compared to PET/magnetic resonance imaging (MRI) in evaluating patients with cancer. PET/CT and PET/MRI may determine which scanner is best for the patient's type of cancer and other types of cancers.

Conditions

  • Cancer Diagnosis
  • Diagnostic Techniques and Procedures
  • Diagnostic Imaging

Interventions

DRUG

F-18 FDG

Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging

DRUG

Ga-68-DOTA-TATE

Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging

DEVICE

Positron Emission Tomography / Computed Tomography (PET/CT) Scan

Scan using a regular medical care (IDE-exempt) Discovery 600 / 690 PET/CT scanner.

DEVICE

Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan

Scan using a NOVEL GE PET/MRI scanner.

Sponsors & Collaborators

Principal Investigators

  • Andrei Iagaru · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-27
Primary Completion
2016-11-30
Completion
2020-02-05
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03125629 on ClinicalTrials.gov